Do analysts prefer PSTV or CURX?

Plus Therapeutics currently has a consensus target price of $51.75, suggesting a potential upside of 1,585.67%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Plus Therapeutics is more favorable than Curanex Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Plus Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, PSTV or CURX?

Plus Therapeutics is trading at a lower price-to-earnings ratio than Curanex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Plus Therapeutics N/A N/A -$22.39M -$2.30 N/A Curanex Pharmaceuticals N/A N/A -$4.22M -$7.80 N/A

Does the media prefer PSTV or CURX?

In the previous week, Curanex Pharmaceuticals had 2 more articles in the media than Plus Therapeutics. MarketBeat recorded 3 mentions for Curanex Pharmaceuticals and 1 mentions for Plus Therapeutics. Plus Therapeutics' average media sentiment score of 0.00 beat Curanex Pharmaceuticals' score of -0.33 indicating that Plus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Plus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Curanex Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer AYTU or CURX?

Aytu BioPharma currently has a consensus target price of $10.75, suggesting a potential upside of 365.37%. Given Aytu BioPharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Aytu BioPharma is more favorable than Curanex Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aytu BioPharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend CURX or ABVC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CURX or ABVC more profitable?

ABVC BioPharma's return on equity of -47.68% beat Curanex Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Curanex Pharmaceuticals N/A -82.07% -79.65% ABVC BioPharma N/A -47.68% -30.97%

Do analysts prefer TXMD or CURX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, ACTU or CURX?

Actuate Therapeutics is trading at a lower price-to-earnings ratio than Curanex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Actuate Therapeutics N/A N/A -$22.23M -$0.87 N/A Curanex Pharmaceuticals N/A N/A -$4.22M -$7.80 N/A

Is ACTU or CURX more profitable?

Curanex Pharmaceuticals' return on equity of -82.07% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Actuate Therapeutics N/A -346.19% -178.40% Curanex Pharmaceuticals N/A -82.07% -79.65%

Does the media favor ACTU or CURX?

In the previous week, Actuate Therapeutics had 11 more articles in the media than Curanex Pharmaceuticals. MarketBeat recorded 14 mentions for Actuate Therapeutics and 3 mentions for Curanex Pharmaceuticals. Actuate Therapeutics' average media sentiment score of 0.79 beat Curanex Pharmaceuticals' score of -0.33 indicating that Actuate Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actuate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Curanex Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Curanex Pharmaceuticals (CURX) Competitors

$4.79 +0.08 (+1.63%)

Closing price 03:58 PM Eastern

Extended Trading

$4.74 -0.04 (-0.88%)

As of 06:25 PM Eastern

Compare

CURX vs. PSTV, AYTU, ABVC, TXMD, and ACTU

Should you buy Curanex Pharmaceuticals stock or one of its competitors? Curanex Pharmaceuticals's main competitors and comparable companies include Plus Therapeutics (PSTV), Aytu BioPharma (AYTU), ABVC BioPharma (ABVC), TherapeuticsMD (TXMD), and Actuate Therapeutics (ACTU). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Curanex Pharmaceuticals compare to Plus Therapeutics?

Plus Therapeutics (NASDAQ:PSTV) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

In the previous week, Curanex Pharmaceuticals had 2 more articles in the media than Plus Therapeutics. MarketBeat recorded 3 mentions for Curanex Pharmaceuticals and 1 mentions for Plus Therapeutics. Plus Therapeutics' average media sentiment score of 0.00 beat Curanex Pharmaceuticals' score of -0.33 indicating that Plus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Plus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Curanex Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Curanex Pharmaceuticals has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. Curanex Pharmaceuticals' return on equity of -82.07% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-230.24%	-198.48%	-73.13%
Curanex Pharmaceuticals	N/A	-82.07%	-79.65%

Plus Therapeutics is trading at a lower price-to-earnings ratio than Curanex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	N/A	N/A	-$22.39M	-$2.30	N/A
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$7.80	N/A

Plus Therapeutics currently has a consensus target price of $51.75, suggesting a potential upside of 1,585.67%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Plus Therapeutics is more favorable than Curanex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

3.3% of Plus Therapeutics shares are owned by institutional investors. 2.5% of Plus Therapeutics shares are owned by insiders. Comparatively, 39.7% of Curanex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Plus Therapeutics beats Curanex Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Curanex Pharmaceuticals compare to Aytu BioPharma?

Aytu BioPharma (NASDAQ:AYTU) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

In the previous week, Curanex Pharmaceuticals had 3 more articles in the media than Aytu BioPharma. MarketBeat recorded 3 mentions for Curanex Pharmaceuticals and 0 mentions for Aytu BioPharma. Aytu BioPharma's average media sentiment score of 0.00 beat Curanex Pharmaceuticals' score of -0.33 indicating that Aytu BioPharma is being referred to more favorably in the media.

Company	Overall Sentiment
Aytu BioPharma	Neutral
Curanex Pharmaceuticals	Neutral

Curanex Pharmaceuticals has lower revenue, but higher earnings than Aytu BioPharma. Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$66.38M	0.37	-$13.56M	-$4.58	N/A
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$7.80	N/A

Curanex Pharmaceuticals has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. Aytu BioPharma's return on equity of -69.93% beat Curanex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-60.17%	-69.93%	-13.25%
Curanex Pharmaceuticals	N/A	-82.07%	-79.65%

Aytu BioPharma currently has a consensus target price of $10.75, suggesting a potential upside of 365.37%. Given Aytu BioPharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Aytu BioPharma is more favorable than Curanex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

33.5% of Aytu BioPharma shares are owned by institutional investors. 4.9% of Aytu BioPharma shares are owned by insiders. Comparatively, 39.7% of Curanex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Aytu BioPharma beats Curanex Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Curanex Pharmaceuticals compare to ABVC BioPharma?

Curanex Pharmaceuticals (NASDAQ:CURX) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Curanex Pharmaceuticals has higher earnings, but lower revenue than ABVC BioPharma. ABVC BioPharma is trading at a lower price-to-earnings ratio than Curanex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$7.80	N/A
ABVC BioPharma	$510K	43.89	-$7.91M	-$0.30	N/A

In the previous week, Curanex Pharmaceuticals had 3 more articles in the media than ABVC BioPharma. MarketBeat recorded 3 mentions for Curanex Pharmaceuticals and 0 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 0.00 beat Curanex Pharmaceuticals' score of -0.33 indicating that ABVC BioPharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Curanex Pharmaceuticals	Neutral
ABVC BioPharma	Neutral

ABVC BioPharma's return on equity of -47.68% beat Curanex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curanex Pharmaceuticals	N/A	-82.07%	-79.65%
ABVC BioPharma	N/A	-47.68%	-30.97%

11.4% of ABVC BioPharma shares are held by institutional investors. 39.7% of Curanex Pharmaceuticals shares are held by insiders. Comparatively, 19.0% of ABVC BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

ABVC BioPharma beats Curanex Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

How does Curanex Pharmaceuticals compare to TherapeuticsMD?

TherapeuticsMD (NASDAQ:TXMD) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

In the previous week, Curanex Pharmaceuticals had 3 more articles in the media than TherapeuticsMD. MarketBeat recorded 3 mentions for Curanex Pharmaceuticals and 0 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 0.00 beat Curanex Pharmaceuticals' score of -0.33 indicating that TherapeuticsMD is being referred to more favorably in the media.

Company	Overall Sentiment
TherapeuticsMD	Neutral
Curanex Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Curanex Pharmaceuticals has a net margin of 0.00% compared to TherapeuticsMD's net margin of -6.64%. TherapeuticsMD's return on equity of -1.09% beat Curanex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	-6.64%	-1.09%	-0.78%
Curanex Pharmaceuticals	N/A	-82.07%	-79.65%

30.7% of TherapeuticsMD shares are owned by institutional investors. 1.7% of TherapeuticsMD shares are owned by company insiders. Comparatively, 39.7% of Curanex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

TherapeuticsMD has higher revenue and earnings than Curanex Pharmaceuticals. Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02M	7.93	-$570K	$0.02	103.50
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$7.80	N/A

Summary

TherapeuticsMD beats Curanex Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

How does Curanex Pharmaceuticals compare to Actuate Therapeutics?

Actuate Therapeutics (NASDAQ:ACTU) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment.

Actuate Therapeutics is trading at a lower price-to-earnings ratio than Curanex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.87	N/A
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$7.80	N/A

Actuate Therapeutics currently has a consensus price target of $13.67, indicating a potential upside of 1,011.11%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Actuate Therapeutics is more favorable than Curanex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Actuate Therapeutics had 11 more articles in the media than Curanex Pharmaceuticals. MarketBeat recorded 14 mentions for Actuate Therapeutics and 3 mentions for Curanex Pharmaceuticals. Actuate Therapeutics' average media sentiment score of 0.79 beat Curanex Pharmaceuticals' score of -0.33 indicating that Actuate Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Actuate Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Curanex Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Curanex Pharmaceuticals' return on equity of -82.07% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-346.19%	-178.40%
Curanex Pharmaceuticals	N/A	-82.07%	-79.65%

Summary

Actuate Therapeutics beats Curanex Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

Get Curanex Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CURX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CURX vs. The Competition

Export

Metric	Curanex Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.39M	$12.53B	$7.36B	$12.81B
Dividend Yield	N/A	2.61%	2.53%	10.78%
P/E Ratio	-0.61	646.74	211.91	20.71
Price / Sales	N/A	753.83	631.75	95.36
Price / Cash	N/A	15.47	29.03	36.89
Price / Book	0.60	10.42	11.18	6.40
Net Income	-$4.22M	$2.79B	$3.46B	$347.95M
7 Day Performance	12.53%	2.25%	1.98%	0.91%
1 Month Performance	27.38%	4.72%	7.32%	5.10%
1 Year Performance	N/A	7.07%	24.76%	16.16%

Curanex Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CURX Curanex Pharmaceuticals	0.5944 of 5 stars	$4.79 +1.6%	N/A	N/A	$7.39M	N/A	N/A	N/A	Positive News Gap Down
PSTV Plus Therapeutics	1.9144 of 5 stars	$3.70 -3.4%	$56.40 +1,424.3%	-74.7%	$25.47M	N/A	N/A	20
AYTU Aytu BioPharma	2.1588 of 5 stars	$2.37 +0.5%	$10.75 +353.4%	+7.7%	$25.44M	$66.38M	N/A	160	Positive News
ABVC ABVC BioPharma	0.3648 of 5 stars	$0.92 -4.1%	N/A	-72.3%	$24.45M	$510K	N/A	30
TXMD TherapeuticsMD	0.9805 of 5 stars	$2.09 +0.5%	N/A	+87.3%	$24.18M	$3.02M	34.83	420	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CURX) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Curanex Pharmaceuticals (CURX) Competitors

CURX vs. PSTV, AYTU, ABVC, TXMD, and ACTU

How does Curanex Pharmaceuticals compare to Plus Therapeutics?

Summary

How does Curanex Pharmaceuticals compare to Aytu BioPharma?

Summary

How does Curanex Pharmaceuticals compare to ABVC BioPharma?

Summary

How does Curanex Pharmaceuticals compare to TherapeuticsMD?

Summary

How does Curanex Pharmaceuticals compare to Actuate Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CURX vs. The Competition

Curanex Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Curanex Pharmaceuticals (CURX) Competitors

CURX vs. PSTV, AYTU, ABVC, TXMD, and ACTU

How does Curanex Pharmaceuticals compare to Plus Therapeutics?

Does the media prefer PSTV or CURX?

Is PSTV or CURX more profitable?

Which has preferable valuation & earnings, PSTV or CURX?

Do analysts prefer PSTV or CURX?

Do institutionals and insiders hold more shares of PSTV or CURX?

Summary

How does Curanex Pharmaceuticals compare to Aytu BioPharma?

Does the media refer more to AYTU or CURX?

Which has better valuation and earnings, AYTU or CURX?

Is AYTU or CURX more profitable?

Do analysts prefer AYTU or CURX?

Do institutionals and insiders hold more shares of AYTU or CURX?

Summary

How does Curanex Pharmaceuticals compare to ABVC BioPharma?

Do analysts recommend CURX or ABVC?

Which has preferable valuation and earnings, CURX or ABVC?

Does the media refer more to CURX or ABVC?

Is CURX or ABVC more profitable?

Do insiders and institutionals hold more shares of CURX or ABVC?

Summary

How does Curanex Pharmaceuticals compare to TherapeuticsMD?

Does the media refer more to TXMD or CURX?

Do analysts prefer TXMD or CURX?

Is TXMD or CURX more profitable?

Do institutionals & insiders believe in TXMD or CURX?

Which has better earnings and valuation, TXMD or CURX?

Summary

How does Curanex Pharmaceuticals compare to Actuate Therapeutics?

Which has higher valuation and earnings, ACTU or CURX?

Do analysts prefer ACTU or CURX?

Does the media favor ACTU or CURX?

Is ACTU or CURX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CURX vs. The Competition

Curanex Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools